fashion -WSS

fashion

author：fashion 2025-10-01 14:59:38 - browse：32

The ability of cancer cells to move and spread depends on actin-rich core structures such as the podosomes (yellow) shown here in melanoma cells. Cell nuclei (blue), actin (red), and an actin regulator (green) are also shown. — Metastatic melanoma cells Julio C. Valencia,/NCI Center for Cancer Research

Nearly four decades after its first conception, the first TIL therapy, an immunotherapy that harvests cancer-fighting immune cells from the patient’s own body, received accelerated approval from the Food and Drug Administration for advanced melanoma. The therapy, called Amtagvi or lifileucel from Iovance, is the first cell therapy approved for a solid tumor.

“It’s so exciting and gratifying,” said Allison Betof Warner, a cell therapy researcher and physician at Stanford University who has worked on Amtagvi. “This is a game-changing moment for our field. We’ve seen huge success of cellular therapy for hematologic malignancies, and we’ve yet to capitalize on that for solid tumors. This is hopefully the first of many to come.”

In a Phase 2 clinical trial, titled C-144-01, 153 patients who had already been on a median of three prior lines of therapy received lifileucel, and 31% of them responded to therapy. “These are in very late line patients. They’ve exhausted every standard care option,” Betof Warner said. “The most promising part of this therapy for me is that 42% of patients who responded were still responding for 18 months or longer. It’s truly incredible.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Can sheer will power keep patients alive in their dying hours?

WSS

Carvykti CAR

Weight loss drugs should be covered by insurers, AMA says

Ventyx halts psoriasis drug development after lackluster trial results

Ohio still needs to do more to protect the right to abortion

In Spain, a hospital brews its own CAR

Ventyx halts psoriasis drug development after lackluster trial results

explore

fashion

focus

Medical records are filled with copy

Readout Newsletter: Zepbound, Valneva's vaccine, and more

ChatGPT in medicine: STAT answers readers' burning questions

Why health care costs have stayed mostly flat since 2010

George Santos makes 1st court appearance after pleading not guilty to 13 counts

Readout Newsletter: The latest on Moderna, Apellis, and Merck

Peter Hotez and the public health issue of online harassment

In Spain, a hospital brews its own CAR

Hollywood unions extend contract negotiations for actors

After decades in use, heart stents finally beat placebo

hotspot

Prime Medicine, Myeloid Therapeutics clash over genome

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Medicare Advantage beneficiaries sue Humana over algorithm use

Prime Medicine, Myeloid Therapeutics clash over genome

What health policies could hitch a ride on a spending bill?

Advocates call out 'SNL' over stereotypes, errors in sickle cell skit

hotspot

focus

leisure time

knowledge